This HCPCS Code Application Summary document includes a summary of each HCPCS code application discussed at the May 13, 2019 HCPCS Public Meeting for Drugs, Biologicals and Radiopharmaceuticals. HCPCS code applications are presented within the summary document in the same sequence as the Agenda for this Public Meeting. Each individual summary includes: the application number, topic; background/discussion of the applicant's request; CMS' published preliminary HCPCS coding recommendation; CMS' published preliminary Medicare payment recommendation; a summary of comments offered on behalf of each applicant at CMS' HCPCS public meeting in response to our preliminary recommendations; and CMS' final HCPCS coding decision. We publish a separate HCPCS Code Application Summary document for each HCPCS Public Meeting held. This is one of a series of five HCPCS Code Application Summaries for CMS' 2019-2020 HCPCS coding cycle.

All requestors will be notified in writing of the final decision regarding the HCPCS code modification request(s) they submitted. At about the same time, the HCPCS Annual Update is published at: https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 1

Application 19.009

TOPIC

Request to modify existing Level II HCPCS code Q4163 which currently reads "Woundex, bioskin, per square centimeter" to include AxoBioMembrane.

Applicants suggested language: Q4163 "Amnion bio, WoundEX, AxoBioMembrane, per square centimeter."

BACKGROUND

Axolotl Biologix, Inc. submitted a request to revise existing HCPCS Level II code Q4163 which currently reads "Woundex, bioskin, per square centimeter" to instead read Amnion, WoundEX, AxoBioMembrane, per square centimeter.

According to the applicant, AxoBioMembrane is indicated for full and partial-thickness, chronic, acute, wounds and hard to heal wounds.

After preparation of the wound site, the human amnion allograft is surgically applied to the wound surface by the physician, extended beyond the wound margin and secured in place using the clinician's choice of fixation. AxoBioMembrane is available in 3 sizes; 1cm x 2cm, 2cm x 3cm, and 4cm x 4cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Amnion Bio or Axobiomembrane, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish Q4211 "Amnion Bio or Axobiomembrane, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 1

Application 19.041

TOPIC

Request to revise existing Level II HCPCS code Q4163 by adding Axolotl Graft and Axolotl DualGraft

Applicant's suggested language: Q4163 “WoundEX, BioSkin, Axolotl Graft, Axolotl DualGraft, per square centimeter.”

BACKGROUND

Axolotl Bilologix, Inc., submitted a request to revise Level II HCPCS code Q4163 which currently reads "WoundEX, bioskin, per square centimeter" to include Axolotl Graft and Axolotl DualGraft.

According to the applicant, these products are "human amniotic allograft, decellularized, dehydrated placental membrane used as a wound barrier, nerve wrap, and serves as a selective membrane to allow for the repair or regeneration of damaged or diseased tissues."

According to the applicant, Axolotl DualGraft is a thicker version of the allograft for wound areas that are more vulnerable to damage. The product is available in four sizes; 1 x 2cm, 2 x 3cm, 4 x 4cm, and 4 x 6cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Axolotl Graft or Axolotl Dualgraft, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish Q4210 "Axolotl Graft or Axolotl Dualgraft, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 1

Application 19.047

TOPIC

Request to establish a single new Level II HCPCS code to identify human amniotic flowable allograft, intended for homologous use and to support the repair of soft tissue injury, Trade names: Axolotl Ambient and Axolotl Cryo.

Applicant's suggested language: QXXXX “Axolotl Ambient, Axolotl Cryo, per milliliter.”

BACKGROUND

Axolotl Biologix, Inc. submitted a request to establish a new single Level II HCPCS code to identify Human amniotic flowable allografts, Trade names: Axolotl Ambient and Axolotl Cryo.

According to the applicant, Axolotl Ambient and Axolotl Cryo are intended for homologous use and to support the repair of soft tissue injury.

The products are applied to the wound surface and/or injected into the wound margins. The products are available in 0.5 ml, 1 ml, and 2 ml dose sizes.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Axolotl Ambient or Axolotl Cryo, 0.1 mg."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4215 "Axolotl Ambient or Axolotl Cryo, 0.1 mg" Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 2

Application 19.099

TOPIC

Request to establish a new Level II HCPCS code to identify a human umbilical tissue membrane allograft, Trade Name: SurgiCORD

Applicant's suggested language: QXXXX "SurgiCORD per sq. cm."

BACKGROUND

Synergy Biologics, LLC submitted a request to establish a new Level II HCPCS code to identify SurgiCORD, a human umbilical tissue membrane allograft.

According to the applicant, indication for use of SurgiCORD is "intented neuropathic ulcers, venous stasis ulcers, post-traumatic and pressure ulcers." "The minimally-processed allograft contains collagen types IV, V, and VII that will promote cellular differentiation and wound healing". SurgiCORD is applied topically to chronic, non-healing wounds. It is available in sizes: 1.5 x 1.5 cm, 3 x 2 cm, 3 x 4 cm and 3 x 6 cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Surgicord, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4218 "Surgicord, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 2

Application 19.100

TOPIC

Request to establish a new Level II HCPCS code to identify a bilayer human amniotic tissue allograft, Trade Name: SurgiGRAFT-DUAL

Applicant's suggested language: QXXXX "SurgiGRAFT-DUAL per sq. cm.”

BACKGROUND

Synergy Biologics, LLC., submitted a request to establish a new Level II HCPCS code to identify SurgiGRAFT-DUAL, a bilayer human amniotic tissue allograft.

According to the applicant, SurgiGRAFT-DUAL is intended for use to repair or replace dermal tissue, including in the treatment of chronic, non-healing wounds including neuropathic ulcers, post-traumatic and pressure ulcers. The minimally-processed bilayer allograft contains collagen types IV, V, and VII that will promote cellular differentiation and wound healing. SurgiGRAFT-DUAL is applied topically to chronic, non-healing wounds. It is available in sizes 2 x 2 cm, 2 x 3 cm, 2 x 4 cm, 2 x 8 CM, 4 x 4 cm; and 12 mm, 15 mm and 18 mm diameter rounds.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Surgigraft-dual, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4219 "Surgigraft-dual, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 3

Application 19.030

TOPIC

Request to establish a new Level II HCPCS code to identify Novafix, a dehydrated human amniotic membrane allograft indicated for use in the management of wounds. Trade name: Novafix™.

Applicant's suggested language: QXXXX "Novafix™, per sq. cm."

BACKGROUND

A request was submitted on behalf of DCI Donor Services, Inc., to establish a new HCPCS Level II code to identify Novafix™.

According to the applicant, Novafix is indicated for use in the management of wounds, including: partial and full thickness wounds, pressure sores/ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (e.g., donor sites, post-laser surgery, post-Mohs surgery, podiatric wounds and wound dehiscence), trauma wounds (abrasions, lacerations, partial thickness burns, skin tears), and draining wounds.

Apply Novafix™ into the wound bed, and position as needed to completely contact the entire surface of the wound bed and extend slightly beyond wound margins. As medically necessary, Novafix™ can be secured to the wound site with the physician’s preferred fixation method based on the type of wound, location of wound, patient's mobility and patient compliance. Novafix is supplied in sizes: 15mm disc, 2cm x 2cm, 4cm x 4cm, and 5cm x 5cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Novafix, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4208 "Novafix, per square centimeter" Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 4

Application 19.031

TOPIC

Request to establish a new Level II HCPCS code to identify SurGraft, a "sheet-like" human amniotic membrane scaffold which "functions as a wound covering". Trade name: SurGraft®.

Applicant's suggested language: QXXXX "SurGraft, per square centimeter."

BACKGROUND

Surgenex, LLC, submitted a request to establish a new HCPCS Level II code to identify SurGraft®, a dehydrated human amniotic membrane allograft.

According to the applicant, SurGraft is "intended for the treatment of non-healing wounds and burn injuries". "SurGraft is directed for use in patients with acute or chronic wounds, including but not limited to, chronic, non-infected, diabetic foot ulcers, chronic, non-infected, partial or full-thickness diabetic foot skin ulcers (due to venous insufficiency), pressure ulcer, surgical wounds and burns which have not adequately responded to conventional therapy." The applicant also stated that "SurGraft is minimally manipulated Human Cell Tissue Product (HCT/P) intended for homologous use"

Surgraft is supplied in five sizes: 2 x 2 cm, 2 x 3, 2 x 4 cm and 4 x 8 cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Surgraft, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

The primary speaker agreed with CMS preliminary recommendation, and described the product as minimally manipulated and for homologous use for acute and chronic wounds which have not responded to conventional therapies.

FINAL DECISION

Establish new Level II HCPCS code Q4209 "Surgraft, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 5

Application 19.101

TOPIC

Request to establish a new Level II HCPCS code to identify an Amniotic/Chorionic Tissue Allograft, Trade Name: AmnioWrap2

Applicant's suggested language: QXXXX "AmnioWrap2, per square cm."

BACKGROUND

A request was submitted on behalf of RegenTX Partners, LLC, to establish a new Level II HCPCS code to identify AmnioWrap2, an Amniotic/Chorionic Tissue Allograft.

According to applicant, AmnioWrap2 is intended for the treatment of wounds, including lower extremity ulceration caused by diabetes, chronic venous disease, and other chronic conditions. Acute wounds involving the dermal tissue layer may be appropriate for treatment with AmnioWrap2. AmnioWrap2 is provided dry in a double foil sterile pouch. It is available in various sizes, from 1 x 1 cm to 10 x 12 cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Amniowrap2, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4221 "Amniowrap2, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 6

Application 19.033

TOPIC

Request to revise existing Level II HCPCS code Q4163 which currently reads "Woundex, bioskin, per square centimeter"; to include "Membrane Graft and Membrane Wrap" human amniotic allograft membranes. Trade names: Membrane Graft and Membrane Wrap.

Applicant's suggested language: Q4163 "Amnion bio, WoundEX, Membrane Graft and Membrane Wrap, per square centimeter."

BACKGROUND

BioLab Sciences, Inc., submitted a request to revise existing Level II HCPCS code Q4163 to include Membrane Graft and Membrane Wrap. According to the applicant, Membrane Graft and Membrane Wrap are Human amniotic allograft membranes used to repair tissue deficits and to reduce healing time for chronic wounds and post-surgical wounds. "The patient population for use of the products includes children and adults suffering from non-healing acute and chronic wounds (diabetic, venous, mixed, venous-arterial, pressure ulcers), complex and/or open surgical wounds and burns."

The product is available in six sizes: 1 x 1cm, 1 x 2cm, 2 x 3cm, 4 x 4cm, 4 x 6cm, and 4 x 8cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Membrane Graft or Membrane Wrap, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

The primary speaker agreed with CMS preliminary recommendation.

FINAL DECISION

Establish new Level II HCPCS code Q4205 "Membrane Graft or Membrane Wrap, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 6

Application 19.034

TOPIC

Request to establish a single new Level II HCPCS code to identify Human amniotic flowable allografts. Trade names: Fluid Flow and Fluid GF.

Applicant’s suggested language: QXXXX “Fluid Flow and Fluid GF, per milliliter.”

BACKGROUND

BioLab Sciences, Inc. submitted a request to establish a single new Level II HCPCS code to identify Human amniotic flowable allografts. Trade names: Fluid Flow and Fluid GF.

According to the applicant, these products are intended for homologous use and support the repair of soft tissue injury by providing natural growth factors and other extracellular components to the injured area to promote healing, reduce inflammation, and reduce healing time. "The patient population indicated for use of Fluid Flow and Fluid GF include acute and chronic wounds and soft tissue injury, muscle and meniscus tears, ligament and tendon sprains, degenerative tissue disorders and Inflammatory conditions (tendonitis and fasciitis)."

The products are available in 0.5cc, 1cc and 2cc sizes.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Fluid Flow or Fluid Gf, 1 cc."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

The primary speaker agreed with CMS preliminary recommendation.

FINAL DECISION

Establish new Level II HCPCS code Q4206 "Fluid Flow or Fluid Gf, 1 cc". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 6

Application 19.074

TOPIC

Request to establish a new Level II HCPCS code to identify an autologous, homologous human skin product. Trade Name: MyOwn Skin™

Applicant's suggested language: QXXXX "MyOwn Skin™, per square centimeter."

BACKGROUND

BioLab Sciences, Inc., submitted a request to establish a new Level II HCPCS code to identify MyOwn Skin™, a fully autologous, homologous skin product. According to the applicant, MyOwn Skin™ is composed of a patient’s own viable skin cells and contains extracellular matrix components to support cellular attachment and proliferation for tissue and skin repair.

MyOwn Skin™ is manufactured from a harvested sample of the patients' partial-thickness skin, composed of viable skin cells and an organized extracellular matrix. It is used to repair tissue deficits and to reduce healing time for chronic wounds and post-surgical wounds, with minimal to no rejection.

The product is available in a variety of sizes, ranging from 1 cm x 1 cm to 10 cm x 10 cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Myown Skin, Includes Harvesting and Preparation Procedures, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

The primary speaker agreed with CMS preliminary recommendation.

FINAL DECISION

Establish new Level II HCPCS code Q4226 "MyOwn skin, includes harvesting and preparation procedures, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 7

Application 19.051

TOPIC

Request to revise existing Level II HCPCS code Q4169 which identifies Artacent™ Wound to include single and dual layer products.

Applicant's suggested revised language: Q4169 “Artacent Wound, single or dual layer, per sq cm.”

BACKGROUND

Tides Medical submitted a request to revise existing Level II HCPCS code Q4169, which currently reads: "Artacent wound, per square centimeter" to instead read: "Artacent wound, single or dual layer, per sq cm".

According to the applicant, "Artacent™ Wound is a dual or single layer human amniotic membrane allograft intended for treatment of acute and chronic wounds such as diabetic ulcers, venous stasis ulcers, burns, and additional wounds that are refractory to more conservative care."

Artacent™ Wound is applied to the wound bed following wound preparation. Absorbable/non-absorbable suture material and/or tissue adhesives may be used to apply the graft to the site, if necessary. Artacent™ Wound is supplied in a variety of sizes.

PRELIMINARY HCPCS CODING RECOMMENDATION

Existing code Q4169 "Artacent wound, per square centimeter", adequately describes the wound products as reflected in the FDA license.

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Existing code Q4169 "Artacent wound, per square centimeter", adequately describes the wound products as reflected in the FDA license.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 7

Application 19.052

TOPIC

Request to establish a new Level II HCPCS code to identify a "healing patch" comprised of Artacent Cord Human Umbilical Cord, Trade Name: Artacent Cord.

BACKGROUND

Tides Medical submitted a request to establish a new Level II HCPCS code to identify Artacent Cord.

According to the applicant, Artacent Cord is "a wound healing patch that is comprised of the umbilical cord." "It is intended for the treatment of acute and chronic wounds such as diabetic ulcers, venous stasis ulcers, burns, and additional wounds that are refractory to more conservative care."

Artacent Cord is applied to the wound bed following wound preparation. Absorbable/non-absorbable suture material and/or tissue adhesives may be used to apply the graft to the site, if necessary. Once applied the allograft can hydrated with sterile saline or other sterile solution, if needed.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Artacent cord, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish Level II HCPCS code Q4216 "Artacent cord, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 8

Application 19.071

TOPIC

Request to establish a new Level II HCPCS code to identify an umbilical cord allograft, Trade Name: Cellesta™ Cord.

Applicant's suggested language: QXXXX "Cellesta™ Cord, per square centimeter."

BACKGROUND

Ventris Medical, LLC, submitted a request to establish a new Level II HCPCS code to identify Cellesta™ Cord, an umbilical cord allograft product.

According to the applicant, Cellesta™ Cord is intended for use as a regenerative wound covering for the treatment of acute, chronic and surgically created wounds.

Cellesta™ Cord can be sutured, or glued, or laid over the desired tissue. It is available in 8 sizes: 3 circular and 5 rectangular: 12 mm, 15 mm, 18 mm, 1.5 x 1.5 cm, 3 x 2 cm, 3 x 4 cm, 3 x 6 cm, and 3 x 8 cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Cellesta cord, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4214 "Cellesta cord, per square centimeter" Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 8

Application 19.072

TOPIC

Request to establish a new Level II HCPCS code to identify a dual layer human amniotic membrane allograft, Trade Name: Cellesta™ Duo.

Applicant's suggested language: QXXXX "Cellesta™ Duo, per square centimeter."

BACKGROUND

Ventris Medical, LLC, submitted a request to establish a new Level II HCPCS code to identify Cellesta™ Duo, a human amniotic membrane allograft. According to the applicant, Cellesta™ Duo is intended for use as a regenerative wound covering for the treatment of acute, chronic and surgically created wounds.

Cellesta™ Duo is available wet or dry in 5 different sizes: 2 x 2 cm, 2 x 4 cm, 2 x 6 cm, 3 x 3 cm, 4 x 4 cm, and 4 x 8 cm. Cellesta™ Duo is a dual allograft affixed to a layer of poly mesh. This can be sutured, or glued, or laid over the affected tissue.

PRELIMINARY HCPCS CODING RECOMMENDATION

Revise existing code Q4184 which currently reads "Cellesta, per square centimeter", to instead read "Cellesta or Cellesta Duo, per square centimeter". Revised code adequately describes Cellesta and Cellesta Duo and will be available for assignment by insurers if they deem appropriate.

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Revise existing code Q4184 which currently reads "Cellesta, per square centimeter", to instead read "Cellesta or Cellesta Duo, per square centimeter". Revised code adequately describes Cellesta and Cellesta Duo and will be available for assignment by insurers if they deem appropriate. Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting
Agenda Item # 9
Application 19.061

TOPIC

Request to establish a new Level II HCPCS code to identify a human amnion allograft, Trade Name: AlloGen Liquid.

Applicants suggested language: QXXXX “AlloGen injectable, per ml.”

BACKGROUND

Vivex Biomedical, Inc., submitted request to establish a new Level II HCPCS code to identify AlloGen.

According to the applicant, "AlloGen is composed of 100% human liquid amnion". It is "an amniotic fluid product derived from donated birth tissue... processed using aseptic techniques..." The allograft is exposed to electron beam radiation... to ensure terminal sterilization. "AlloGen is intended for treatment of non-healing wounds and burn injuries." The applicant claims that use of AlloGen liquid for the treatment of non-healing wounds and burn injuries is a homologous use in that. "Just as amniotic fluid protects and nourishes the fetus during development, AlloGen provides the same protection to injured or traumatized tissue."

The dosage of AlloGen is per cubic centimeter (cc). It is intended for external application. It is supplied in single use vials ranging from 0.25 to 2.0 ml.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Allogen, per cc."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4212 "Allogen, per cc". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 10

Application 19.063

TOPIC

Request to establish a new Level II HCPCS code to identify a "dehydrated cell and protein concentrate (dCPC) injectable derived from human amniotic fluid", Trade Name: Ascent™.

Applicant suggested language: Qxxxx “Ascent™, per milligram.”

BACKGROUND

StimLabs, LLC, submitted a request to establish a new Level II HCPCS code to identify Ascent™, a dehydrated cell and protein concentrate (dCPC) injectable derived from human amniotic fluid. According to the applicant, Ascent™ combines a selected set of cells from amniotic fluid and their components, including TIMPs, growing factors, interleukins and hyaluronic acid. Through complex interactions, these components work together to provide protecting, cushioning, lubrication, and inflammation reduction at the site of injury. Ascent™ is intended for the treatment of non-healing wounds and burn injuries. Ascent™ is offered in 7.5 mg, 15 mg, and 30 mg powdered weight. The suggested reconstitution volumes are 0.5 cc, 1 cc, and 2 cc respectively giving a 0.75%, 1.5% and 3% dose. Ascent™ is reconstituted using sterile saline based on recommended reconstitution amounts.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Ascent, 0.5 mg."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4213 "Ascent, 0.5 mg". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 11

Application 19.088

TOPIC

Request to establish a single new Level II HCPCS code to identify WoundFix™ Membrane BioWound™ Membrane.

Applicant's suggested language: Q41XX “WoundFixTM Membrane & BioWoundTM Membrane, per square centimeter.”

BACKGROUND

A request was submitted on behalf of Human Regenerative Technologies, LLC, to establish a single new Level II HCPCS code to identify human amnion-based membranes: WoundFix™ and BioWound™

According to the applicant, WoundFix™ and BioWound™ membranes are single-layer wound coverings for common wounds. These are intended for use as a wound covering, surgical covering, wrap or barrier, application to partial-and full-thickness, acute and chronic wounds such as, traumatic and complex wounds, burns, surgical and Mohs surgery sites and diabetic, venous, arterial, pressure and other ulcers, including with exposed tendon, muscle, bone, or other vital structures.

These products are supplied in single use packaging in sizes ranging from .786 to 486 sq. cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Woundfix, Biowound, Woundfix Plus, Biowound Plus, Woundfix Xplus or Biowound Xplus, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4217 "Woundfix, Biowound, Woundfix Plus, Biowound Plus, Woundfix Xplus or Biowound Xplus, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 11

Application 19.089

TOPIC

Request to establish a single new Level II HCPCS code to identify human, chorion-based membranes. Trade Names: WoundFix™ Plus Membrane and BioWound™ Plus Membrane

Applicant's suggested language: Q41XX “WoundFix™ Plus Membrane & BioWound™ Plus Membrane, per square centimeter.”

BACKGROUND

A request was submitted on behalf of Human Regenerative Technologies, LLC, to establish a single new Level II HCPCS code to identify human, chorion-based membranes: WoundFix™ Plus and BioWound™ Plus.

According to the applicant, WoundFix™ Plus and BioWound™ Plus membranes are single layer wound coverings intended for use as a wound covering, surgical covering, wrap or barrier, application to partial-and full-thickness, acute and chronic wounds such as traumatic and complex wounds, burns, surgical and Mohs surgery sites and diabetic, venous, arterial, pressure and other ulcers, including with exposed tendon, muscle, bone, or other vital structures.

Typically, one application is applied per wound; however, the product may be reapplied if necessary. WoundFix™ Plus and BioWound™ Plus membrane are supplied in single use packaging in sizes ranging from .786 to 192 sq. cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Woundfix, Biowound, Woundfix Plus, Biowound Plus, Woundfix Xplus or Biowound Xplus, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4217 "Woundfix, BioWound, Woundfix Plus, BioWound Plus, Woundfix Xplus or BioWound Xplus, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 11

Application 19.090

TOPIC

Request to establish a single new Level II HCPCS code to identify human placental tissue based membranes. Trade Names: WoundFix™ XPlus Membrane and BioWound™ XPlus Membrane.

Applicant's suggested language: Q41XX “WoundFix™ XPlus Membrane & BioWound™ XPlus Membrane, per square centimeter.”

BACKGROUND

A request was submitted on behalf of Human Regenerative Technologies, LLC, to establish a single new Level II HCPCS code to identify WoundFix™ XPlus Membrane and BioWound™ XPlus human placental tissue-based membranes.

According to the applicant, WoundFix™ XPlus Membrane and BioWound™ XPlus Membrane are single layer wound coverings intended to be used as a wound covering, surgical covering, wrap or barrier, application to partial-and full-thickness, acute and chronic wounds such as, traumatic and complex wounds, burns, surgical and Mohs surgery sites and diabetic, venous, arterial, pressure and other ulcers, including with exposed tendon, muscle, bone, or other vital structures.

WoundFix™ XPlus Membrane and BioWound™ XPlus Membrane are supplied in single-use packaging, in 6 sq. cm and 12 sq. cm. sizes.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Woundfix, BioWound, Woundfix Plus, BioWound Plus, Woundfix Xplus or BioWound Xplus, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4217 "Woundfix, BioWound, Woundfix Plus, BioWound Plus, Woundfix Xplus or BioWound Xplus, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 12

Application 19.036

TOPIC

Request to establish a new Level II HCPCS code to identify a human acellular dehydrated dermis regenerative tissue matrix. Trade name: BellaCell HD.

Applicant’s suggested language: “BellaCell HD Regenerative Tissue Matrix, per square centimeter.”

BACKGROUND

HansBiomed Corp., submitted a request to establish a new HCPCS Level II code to describe BellaCell HD, a human acellular dehydrated dermis regenerative tissue matrix.

According to applicant, BellaCell HD is indicated "for use in skin reconstruction to repair skin loss from burn injuries, congenital diseases, abdominal wall repair, hiatal hernia repair, breast reconstruction, and ulcers or malformation."

BellCell HD is supplied as 1.0-1.39mm, 1.4-1.79mm, 1.8-2.29mm, 2.3-2.99mm and 3.0-3.49mm

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Bellacell HD or Surederm, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4220 "Bellacell HD or Surederm, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 12

Application 19.037

TOPIC

Request to establish a new Level II HCPCS code to identify a human acellular dermal matrix.
Trade name: SureDerm.

Applicant’s suggested language: “SureDerm Acellular Dermal Matrix, per square centimeter.”

BACKGROUND


According to applicant, SureDerm is indicated for use in "skin reconstruction to repair skin loss from burn injuries, car accidents, congenital diseases, periodontal diseases, urinary incontinence, and ulcers or malformations."

SureDerm is supplied as 0.25-0.59mm, 0.6-0.99mm, 1.0-1.39mm, 1.4-1.79mm and 1.8mm and over

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Bellacell HD or Surederm, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4220 "Bellacell HD or Surederm, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 13

Application 19.055

TOPIC

Request to establish a new Level II HCPCS code to identify Human Keratin Matrix derived from human hair. Trade Name: ProgenaMatrix™.

BACKGROUND

A request was submitted on behalf of Cell Constructs I, LLC, to establish a new Level II HCPCS code to identify a graft matrix composed of human keratin proteins selectively extracted from human hair. Trade Name: ProgenaMatrix™

According to the applicant, "ProgenaMatrix™ is indicated for dry and exuding partial and full thickness wounds such as pressure (stage I-IV) and venous stasis ulcers, ulcers caused by mixed vascular etiologies, diabetic ulcers, donor sites and grafts, first and second-degree burns, superficial injuries, cuts, abrasions and surgical wounds."

ProgenaMatrix™ is applied directly to the wound bed after debridement of the wound site to remove necrotic debris, biofilm, and non-viable tissue. Each matrix provides the same amount of human keratin proteins per square centimeter of product. It is supplied in sizes: 2cm x 2cm, 4cm x 4cm, 6cm x 6cm, 10cm x 10cm; and 12cm x 12cm.

PRELIMINARY HCPCS CODING RECOMMENDATION

Establish Q42XX "Progenamatrix, per square centimeter."

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Establish new Level II HCPCS code Q4222 "Progenamatrix, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 14

Application 19.059

TOPIC

Request to revise existing Level II HCPCS code Q4165 "Keramatrix, per square centimeter" to add an additional similar product, Kerasorb.

Applicant's suggested language: Q4165 “Keramatrix, per square centimeter or Kerasorb Wound Matrix, per square centimeter.”

BACKGROUND

A request was submitted on behalf of Keraplast Research Limited, to revise existing Level II HCPCS code Q4165 which currently reads: "Keramatrix, per square centimeter" to instead read: "Keramatrix, per square centimeter or Kerasorb Wound Matrix, per square centimeter".

According to the applicant, "Kerasorb Wound Matrix is clinically indicated for the patient population with the following types of chronic wounds: pressure ulcers (stages I-IV), venous stasis ulcers, ulcers caused by mixed vascular etiologies, diabetic ulcers, and donor sites and grafts."

Kerasorb is supplied in single use pouches containing one 10 cm x 10 cm foam wound matrix. It is applied to the wound area using aseptic technique similar to Keramatrix and other cellular and/or tissue based products for the skin wounds.

PRELIMINARY HCPCS CODING RECOMMENDATION

Revise existing code Q4165, which currently reads "Keramatrix, per square centimeter", to instead read "Keramatrix or Kerasorb, per square centimeter". Revised code Q4165 adequately describes Keramatrix and Kerasorb and will be available for assignment by insurers if they deem appropriate.

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION
Revise existing code Q4165, which currently reads "Keramatrix, per square centimeter", to instead read "Keramatrix or Kerasorb, per square centimeter". Effective 10/1/19.
TOPIC

Request to revise existing Level II HCPCS code Q4122, which currently reads: "DermACELL, per square centimeter" to instead read: "DermACELL, DermACELL AWM, DermACELL AWM Porous, per square centimeter."

BACKGROUND

LifeNet Health submitted a request to revise existing Level II HCPCS code Q4122, which currently reads: "DermACELL, per square centimeter" to instead read: "DermACELL, DermACELL AWM, DermACELL AWM Porous, per square centimeter."

According to applicant, DermACELL, DermACELL AWM, DermACELL AWM Porous "are decellularized human dermal allografts" indicated for use in "chronic non-healing wounds such as diabetic and venous leg ulcers, acute burns, breast reconstruction and other associated soft tissue injuries."

The grafts comes in various sizes, from 4 to 320 square centimeters and from 0.2 - 3.5 mm thick.

PRELIMINARY HCPCS CODING RECOMMENDATION

Revise existing code Q4122, which currently reads, "Dermacell, per square centimeter", to instead read "Dermacell, Dermacell Awm or Dermacell Awm Porous, per square centimeter". Revised code Q4122 adequately describes Dermacell, Dermacell Awm or Dermacell Awm Porous, and will be available for assignment by insurers if they deem appropriate.

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Revise existing code Q4122, which currently reads, "Dermacell, per square centimeter", to instead read "Dermacell, Dermacell Awm or Dermacell Awm Porous, per square centimeter". Effective 10/1/19.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 16

Application 19.070

TOPIC

Request to establish a new Level II HCPCS code to identify an allograft adipose matrix, Trade Name: Renuva®

Applicant's suggested language: Qxxxx "Renuva Allograft Adipose Matrix, 0.5cc."

BACKGROUND

The Musculoskeletal Transplant Foundation submitted a request to establish a new Level II HCPCS code to identify Renuva®, an Allograft Adipose Matrix, derived from processed donated human adipose tissue.

According to the applicant, "Renuva is intended for the replacement of damaged or inadequate integumental adipose tissue matrix such as facial deformities, craniofacial deformities, breast reconstructions, or for other homologous uses into areas of the body where native fat would exist. Renuva® Allograft Adipose Matrix may also be used for the reinforcement or supplemental support in underlying adipose tissue matrix as the result of damage or naturally occurring defects e.g., cleft lip, Parry-Romberg syndrome, and facial LDS." The matrix is dehydrated and must be rehydrated prior to use. When ready to use, the allograft is injected into the site subcutaneously. The matrix is available in three sizes: 1.5cc, 3cc and 5cc tissue package.

PRELIMINARY HCPCS CODING RECOMMENDATION

The CMS spent a significant amount of time carefully considering this application and in the process, communicated with the applicant several times, in February, March and April of this year, and researching policy information and other supplemental materials provided by the applicant. Yet CMS was unable to find policy on the part of any insurance sector that would indicate a need for a code to identify a non-autologous adipose graft for the clinical indications specified by the applicant, in a physician’s office setting.

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

The primary speaker disagreed with CMS preliminary recommendation. The speaker commented that CMS decision wrongly mixes coding and coverage. Nowhere in HCPCS Level II Coding procedure or other HCPCS guidance documents does it state that a product must be used in physician office setting in order to be granted a Level II HCPCS code. Renuva is expected to be used approximately 80% of the time in the physician office.
FINAL DECISION

The CMS spent a significant amount of time carefully considering this application and in the process, communicated with the applicant several times, in February, March and April of this year, and researching policy information and other supplemental materials provided by the applicant. CMS also accepted a single billing document provided by the applicant following the May 13th, 2019 HCPCS public meeting, as well as additional information provided to CMS during in-person meeting on 09/20/2019. Yet CMS was unable to find policy on the part of any insurance sector that would indicate a need for a code to identify a non-autologous adipose graft for the clinical indications specified by the applicant, in a physician's office setting.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 17

Application 19.004

TOPIC

Request to establish a single new Level II HCPCS code to identify a 100% native, freeze-dried, Type-I bovine Collagen matrix for use for wound management, Trade names: ACM Surgical Collagen and ACM Surgical Extra Advanced Collagen.

Applicant's suggested language: QXXXX "ACM Surgical Collagen/ACM Surgical Extra Advanced Collagen, per square centimeter.”

BACKGROUND

A request was submitted on behalf of Human Biosciences Inc., to establish a new level II HCPCS code to identify ACM Surgical Collagen and ACM Surgical Extra Advanced Collagen, 100% native, freeze-dried, type-I bovine collagen matrix, provided in a collagen sheet configuration.

According to the applicant, ACM Surgical Collagen and ACM Surgical Extra Advanced Collagen are indicated for use as a scaffold in the "management of partial and full-thickness wounds [i.e. surgical wounds, donor sites, graft sites, second degree burns, traumatic wounds (pressure, venous, mixed vascular etiologies, diabetic ulcers)] to support healing".

ACM Surgical Collagen and ACM Surgical Extra Advanced Collagen is administered by applying each individual matrix directly to the wound surface after preparation of the wound site to remove necrotic debris, biofilm, and non-viable tissue, using the clinician's choice of fixation. Each matrix provides the same amount of collagen per square centimeter of product. Usually one tissue is applied per application. Additional applications may be required, based on physician choice. These products are packaged in sterile, single-use pouches and available in sheet sizes: 2"x2", 4"x4", 4"x5", 7x7", 8"x12".

PRELIMINARY HCPCS CODING RECOMMENDATION

Existing codes A6021 "Collagen dressing, sterile, size 16 square inch or less, each", A6022 "Collagen dressing, sterile, size more than 16 sq inch but less than or equal to 4 sq. in., each", or A6023 "Collagen dressing, sterile, size more than 48 sq in., each", depending on size, adequately describes ACM Surgical collagen and ACM Surgical extra advanced collagen. These codes are available for assignment by insurers if they deem appropriate.
SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Existing codes A6021 "Collagen dressing, sterile, size 16 square inch or less, each", A6022 "Collagen dressing, sterile, size more than 16 sq inch but less than or equal to 4 sq. in., each", or A6023 "Collagen dressing, sterile, size more than 48 sq in., each", depending on size, adequately describes ACM Surgical collagen and ACM Surgical extra advanced collagen. These codes are available for assignment by insurers if they deem appropriate.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 17

Application 19.113

TOPIC

Request to establish a new Level II HCPCS code to describe a 100% native Type 1 bovine collagen powder for use in wound management, Trade Name: ACM Surgical Extra Advanced Collagen Powder.

Applicants suggested language: QXXXX "ACM Surgical Extra Advance Collagen Powder, per gm."

BACKGROUND

A request was submitted on behalf of Human Biosciences, to establish a Level II HCPCS code to identify ACM Surgical Extra Advanced Collagen Powder.

According to the applicant, ACM Surgical Extra Advanced Collagen Powder "is indicated for wound management of partial and full-thickness wounds such as second degree burns, ulcers (pressure, venous, mixed vascular etiologies, diabetic ulcers) and other wounds (e.g. surgical wounds, scrapes, traumatic wounds)."

The product is applied directly to the wound surface after preparation of the wound site to remove necrotic debris, biofilm, and non variable tissue. It is supplied as sterile, single-use 1gm pouch, 1gm vial, 5gm vial and 10gm bottle.

PRELIMINARY HCPCS CODING RECOMMENDATION

Existing code A6010 "Collagen based wound filler, dry form, sterile, per gram of collagen", adequately describes ACM surgical extra advanced collagen powder and is available for assignment by insures if they deem appropriate.

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.
FINAL DECISION

Existing code A6010 "Collagen based wound filler, dry form, sterile, per gram of collagen", adequately describes ACM surgical extra advanced collagen powder and is available for assignment by insures if they deem appropriate.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 18

Application 19.087

TOPIC

Request to revise existing Level II HCPCS code Q4133 which currently reads: "Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter", to omit Stravix products, and to instead read: "Grafix PRIME® and GrafixPL PRIME, per square centimeter"; and request to establish a new Level II HCPCS code to identify Stravix and StravixPL.

Applicant's suggested language: "QXXXX Stravix, and StravixPL, per square centimeter."

BACKGROUND

Osiris Therapeutics, Inc., submitted a request to un-do the result of its prior year application to include Stravix and Grafix products in the same code; and to instead create a coding distinction between the Stravix and Grafix. Specifically, in the current coding cycle, Osiris asked CMS to establish a new Level II HCPCS code to identify Stravix® and StravixPL™; and to revise the descriptor of existing code Q4133 "Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter", to omit Stravix, and Stravix PL, on the basis that Stravix products are thicker than Grafix and that insurers treat that product differently.

According to applicant Grafix prime, GrafixPL prime and Stravix/StravixPL are both placental tissue allografts indicated for use on wound repair for the following indications: diabetic foot ulcer, venous leg ulcers, pressure ulcers, dehisced surgical wounds, burns, acute surgical wounds, pyoderma gangrenosum, and epidermolysis bullosa, including complex wounds with exposed bone, tendon and hardware, and chronic recalcitrant wounds of various etiologies in peripheral arterial disease (PAD). Specifically, Stravix/StraviPL are used for deeper wounds in higher risk patients and the wounds located in areas subject to high shear force. The quantity and size of the product used will vary based upon wound size and physician recommendation. Stravix/StravixPL are approximately 10 times thicker than Grafix PRIME and GrafixPL PRIME and dosing recommendation is weekly for up to 12 weeks or until the wound is closed.

PRELIMINARY HCPCS CODING RECOMMENDATION

CMS supports its 2018-2019 coding cycle decision honoring Osiris' prior request to include Grafix and Stravix products together in existing code Q4133. Existing code Q4133 "Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter", adequately describes the Stravix and Grafix products that are subject to this application.
SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.

FINAL DECISION

Existing code Q4133 "Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter", adequately describes the Stravix and Grafix products that are subject to this application.
May 13, 2019

CMS HCPCS Public Meeting

Agenda Item # 19

Application 19.068

TOPIC

Request to establish a new Level II HCPCS code to identify acellular dermal matrix, Trade Name: Artia.

BACKGROUND

Allergan USA Inc. submitted a request to establish a new Level II HCPCS code to identify Artia™, a sterile, acellular dermal matrix (ADM) developed for use in plastic and reconstructive surgery, specifically designed to have handling characteristics and biologic response similar to Alloderm™ Regenerative Tissue Matrix. It is manufactured by Allergan USA Inc.

According to the applicant, Artia™ is intended for use as a soft tissue patch to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue membranes, which require the use of reinforcing or bridging material to obtain the desired surgical outcome.

Based on each individual patient case, the physician will determine the most appropriate size and shape of Artia™ to use on the patient. Artia™ is implanted in a surgically created subcutaneous space during plastic and reconstructive procedures, and is sutured to the patient's own adjacent soft tissue under appropriate physiologic tension.

PRELIMINARY HCPCS CODING RECOMMENDATION

Artia is not suitable for coding in Level II HCPCS as it is used exclusively in hospital inpatient and outpatient settings. For inpatient use, Artia would be bundled in hospital payment. CMS refers applicant to CMS' pass-through coding program for consideration of pass-through coding for use HOPPS settings.

SUMMARY OF PRIMARY SPEAKER COMMENTS AT THE PUBLIC MEETING

No comment was offered from the applicant at CMS HCPCS Public Meeting in response to our Preliminary recommendations.
FINAL DECISION

Artia is not suitable for coding in Level II HCPCS as it is used exclusively in hospital inpatient and outpatient settings. For inpatient use, Artia would be bundled in hospital payment. CMS refers applicant to CMS' pass-through coding program for consideration of pass-through coding for use HOPPS settings.